Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-cash Items (2021 - 2024)

Gain Therapeutics has reported Non-cash Items over the past 4 years, most recently at $1.9 million for Q4 2024.

  • Quarterly results put Non-cash Items at $1.9 million for Q4 2024, up 25.8% from a year ago — trailing twelve months through Dec 2024 was $1.9 million (up 25.8% YoY), and the annual figure for FY2024 was $1.9 million, up 25.8%.
  • Non-cash Items for Q4 2024 was $1.9 million at Gain Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Non-cash Items for GANX hit a ceiling of $2.6 million in Q2 2022 and a floor of $11.54 in Q1 2021.
  • Median Non-cash Items over the past 4 years was $1.3 million (2021), compared with a mean of $1.1 million.
  • Peak annual rise in Non-cash Items hit 18162811.61% in 2022, while the deepest fall reached 74.38% in 2022.
  • Gain Therapeutics' Non-cash Items stood at $163237.0 in 2021, then plummeted by 80.14% to $32421.0 in 2022, then skyrocketed by 4576.15% to $1.5 million in 2023, then increased by 25.8% to $1.9 million in 2024.
  • The last three reported values for Non-cash Items were $1.9 million (Q4 2024), $1.5 million (Q4 2023), and $32421.0 (Q3 2022) per Business Quant data.